Deciphera's Ripretinib Cuts GIST Death Risk By 64%; US Filing On Track For Early 2020
Executive Summary
Overall survival for patients with gastrointestinal stromal tumors (GIST) in the fourth-line setting was 15.1 months versus 6.6 months for placebo, building on impressive progression-free survival results.
You may also be interested in...
Deciphera’s Qinlock Hits GIST Roadblock With Phase III Failure
The drug remains likely to get approval in Europe, but for now stuck in fourth-line treatment. The company’s pipeline lacks other near-term catalysts.
FDA Approval Makes Deciphera’s Qinlock First Fourth-Line GIST Drug
Qinlock (ripretinib), approved as the US FDA rejected Blueprint Medicines’ Ayvakit (avapritinib) in the same indication, is priced on par with the rival drug cleared in January for a narrower GIST use.
Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data
CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.